Modernization of high and maximum containment research facilities at the National Emerging Infectious Diseases Laboratories (NEIDL) to meet current and future national research priorities09/17/2024 - 05/31/2029 (PI)
NIH/Office of the Director1C06OD037773-01
National Emerging Infectious Diseases Laboratories Operations07/08/2021 - 06/30/2026 (PI)
NIH/National Institute of Allergy & Infectious Diseases5UC7AI095321-11
Assays in Support of Filovirus Nonhuman Primate Studies for Advancement of Medical Countermeasures04/14/2022 - 12/31/2025 (Subcontract PI)
Battelle Memorial Institute HHS ASPR BARDA
Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) Against BSL-4 Pathogens in NHPs06/23/2020 - 11/28/2025 (Subcontract PI)
Battelle Memorial Institute NIH NIAID
Uncovering the RNA regulatory Mechanisms driving pathogenicity at mass-caualty viruses: Merging the technologies of RNA biology and enhanced biosafety to create the next generation of broad spectrum,10/01/2022 - 09/30/2025 (Multi-PI)
PI:
Nancy J. Sullivan, ScDHoward Hughes Medical Institute
GLP Natural History Studies in Nonhuman Primate Models of Filovirus Infection11/01/2023 - 09/28/2025 (Subcontract PI)
Battelle Memorial Institute HHS ASPR BARDA
Pilot Study To Assess Protection against Filovirus challenge by an infused monoclonal antibody10/31/2019 - 08/30/2025 (Subcontract PI)
Leidos NIH NCI75N91019D00024
Determine the Efficacy of Obeldesivir, the Oral Remdesivir Prodrug, to Mitigate od Treat Illness Caused by Nipah Virs Infection - Non-GLP03/08/2024 - 07/31/2025 (Subcontract PI)
Battelle Memorial Institute JPEO-CBRND
Development of a Sudan ebolavirus vaccine utilizing a live vesicular stomatitis virus chimera platform: NHP Study 312/01/2023 - 06/30/2025 (Subcontract PI)
International AIDS Vaccine Initative Inc. HHS ASPR BARDA
Restricted: Pilot Study To Assess Protection against Filovirus challenge by an infused monoclonal antibody10/31/2019 - 06/16/2025 (Subcontract PI)
Leidos NIH NCI75N91019D00024
Showing 10 of 17 results.
Show All Results
Multispecific mAbs characterization - RCVSV Resistance Assay04/01/2024 - 03/31/2025 (PI)
ModeX Therapeutics, Inc.
Task 2 Evaluation of MBP1F5 in Grivets Challenged with Nipah Virus Bangladesh07/18/2023 - 03/31/2025 (Subcontract PI)
Mapp Biopharmaceutical, Inc. DOD ACC
Quantification of Nipah viral RNA in animal samples from NEIDL-11110/11/2024 - 01/31/2025 (Subcontract PI)
Leidos NIH NCI
Multispecific mAbs characterization - RCVSV Resistance Assay09/01/2024 - 01/31/2025 (PI)
ModeX Therapeutics, Inc.
SO2: Purchase and housing of African Green Monkeys for use in CEPI High Containment Animal Studies04/01/2022 - 01/31/2025 (PI)
Coalition for Epidemic Preparedness Innovations
Model Development and Medical Counter Measures (MCMs) for BSL-4 Agents in NHPs03/16/2022 - 12/12/2024 (PI)
NIH/National Institute of Allergy & Infectious Diseases
Accelerated development of a SARS-CoV-2 vaccine based on the live VSVG chimeric virus platform02/26/2021 - 09/30/2024 (Subcontract PI)
International AIDS Vaccine Initative Inc. DOD DTRA